Long-Term Outcomes with Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients

OBJECTIVE: Tyrosine kinase inhibitor (TKI) is the standard treatment for chronic myeloid leukemia (CML). In the national list of essential medicines in Thailand, the first, second, and third-line treatments are imatinib, nilotinib, and dasatinib, sequentially, different from the European Leukemia Ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Towachiraporn, Saikhuan, Punnachet, Teerachat, Hantrakun, Nonthakorn, Piriyakhuntorn, Pokpong, Rattanathammethee, Thanawat, Hantrakool, Sasinee, Chai-Adisaksopha, Chatree, Rattarittamrong, Ekarat, Norasetthada, Lalita, Tantiworawit, Adisak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495903/
https://www.ncbi.nlm.nih.gov/pubmed/37247270
http://dx.doi.org/10.31557/APJCP.2023.24.5.1513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495903/
https://www.ncbi.nlm.nih.gov/pubmed/37247270
http://dx.doi.org/10.31557/APJCP.2023.24.5.1513

Ejemplares similares